New drug combo targets Hard-to-Treat cancers in early trial

NCT ID NCT07176975

Terminated Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This early-phase study tests a new drug, BI 1831169, combined with an existing immunotherapy (nivolumab) in Japanese adults with advanced solid tumors that have spread or not responded to prior treatments. The main goal is to find a safe, tolerable dose. Up to 46 participants will receive the combination as an infusion for up to one year, with regular monitoring for side effects and tumor changes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BI 1831169 and nivolumab
What this could lead to: If it works, this could point toward a new combination treatment for advanced solid tumors that have stopped responding to other therapies.
What could go wrong: This is a very early, small Phase 1 trial focused on safety and dosing, not on proving the treatment works. Many similar experimental combinations fail to show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Locations

National Cancer Center Hospital East

Chiba, Kashiwa, 277-8577, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.